PerkinElmer Completes Acquisition of Antibody and Reagent Leader BioLegend

WALTHAM, Mass. –(BUSINESS WIRE)–Sep. 17, 2021– PerkinElmer, Inc. (NYSE: PKI) a global leader committed to innovating for a healthier world, today announced it has completed its acquisition of BioLegend ,   a leading, worldwide provider of life science antibodies and reagents for a total

close

Get every new post delivered right to your inbox.

Original Source